InvestSMART

Truscreen Group Limited (ASX:TRU)

ALERT: Price-sensitive ASX Announcement for TRU
Current share price for TRU : $0.013 -0.003 (-18.75%)+
Announcement
Release
11 Feb 2026 8:03AM
Price at Release
$0.016
Full Release
download
Summary
TruScreen Group Limited, a leader in AI-enabled cervical cancer screening, announced the validation of its device as a superior primary screening tool for cervical cancer in the world's largest study of opto-electronic screening. Conducted by the Chinese Obstetricians and Gynaecologists Association (COGA) across 64 hospitals in China between 2018 and 2021, this study involved 14,982 women. The results, published in BMC Cancer, demonstrated TruScreen's superior sensitivity and negative predictive value compared to Liquid Based Cytology (LBC) and comparable performance to high-risk HPV DNA testing. TruScreen's technology offers significant advantages for regions with limited laboratory infrastructure, making it a potential game-changer for cervical cancer screening, especially in emerging markets.
Key Points
  • TruScreen validated as superior primary cervical cancer screening tool.
  • Study conducted in 64 hospitals across 9 provinces in China.
  • 14,982 women participated in the study from 2018 to 2021.
  • TruScreen compared with LBC and hrHPV testing.
  • Results showed superior sensitivity and negative predictive value.
  • Study published in BMC Cancer journal.
  • Technology suitable for areas with low pathology infrastructure.
  • Potential to significantly enhance global cervical cancer screening rates.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.